Nothing Special   »   [go: up one dir, main page]

HK1035726A1 - A vla-4 inhibitor: omepupa-v - Google Patents

A vla-4 inhibitor: omepupa-v

Info

Publication number
HK1035726A1
HK1035726A1 HK01106420A HK01106420A HK1035726A1 HK 1035726 A1 HK1035726 A1 HK 1035726A1 HK 01106420 A HK01106420 A HK 01106420A HK 01106420 A HK01106420 A HK 01106420A HK 1035726 A1 HK1035726 A1 HK 1035726A1
Authority
HK
Hong Kong
Prior art keywords
omepupa
inhibitor
vla
cell
methylphenylamino
Prior art date
Application number
HK01106420A
Other languages
English (en)
Inventor
Wen-Cherng Lee
Alan Gill
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1035726A1 publication Critical patent/HK1035726A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01106420A 1998-05-28 2001-09-11 A vla-4 inhibitor: omepupa-v HK1035726A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8706498P 1998-05-28 1998-05-28
PCT/US1999/011924 WO1999061421A1 (en) 1998-05-28 1999-05-28 A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (1)

Publication Number Publication Date
HK1035726A1 true HK1035726A1 (en) 2001-12-07

Family

ID=22202907

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01106420A HK1035726A1 (en) 1998-05-28 2001-09-11 A vla-4 inhibitor: omepupa-v

Country Status (31)

Country Link
US (1) US6495525B1 (xx)
EP (1) EP1082302B1 (xx)
JP (1) JP2002516309A (xx)
KR (1) KR100636713B1 (xx)
CN (1) CN1148350C (xx)
AT (1) ATE256659T1 (xx)
AU (1) AU764108B2 (xx)
BG (1) BG65021B1 (xx)
CA (1) CA2333656C (xx)
CZ (1) CZ298413B6 (xx)
DE (1) DE69913687T2 (xx)
DK (1) DK1082302T3 (xx)
EA (1) EA002988B1 (xx)
EE (1) EE04639B1 (xx)
ES (1) ES2211096T3 (xx)
HK (1) HK1035726A1 (xx)
HU (1) HUP0102255A3 (xx)
IL (1) IL139967A (xx)
IS (1) IS5737A (xx)
MX (1) MXPA00011774A (xx)
NO (1) NO317990B1 (xx)
NZ (1) NZ509199A (xx)
PL (1) PL198189B1 (xx)
PT (1) PT1082302E (xx)
SI (1) SI1082302T1 (xx)
SK (1) SK285280B6 (xx)
TR (1) TR200100190T2 (xx)
UA (1) UA65623C2 (xx)
WO (1) WO1999061421A1 (xx)
YU (1) YU75500A (xx)
ZA (1) ZA200007300B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
CA2309341A1 (en) * 1997-11-24 1999-06-03 Merck & Co., Inc. Substituted .beta.-alanine derivatives as cell adhesion inhibitors
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
NZ511062A (en) * 1998-09-14 2003-04-29 Univ Texas Antagonists of alpha4 containing integrins, which inhibit the biological effects of adhesion interaction in myeloma bone disease
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1265606B9 (en) 1999-08-13 2007-02-28 Biogen Idec MA Inc. Cell adhesion inhibitors
CZ20022072A3 (cs) 1999-12-28 2003-05-14 Pfizer Products Inc. Nepeptidylové inhibitory VLA-4 dependentní buněčné vazby použitelné pro léčbu zánětlivých, autoimunitních a respiračních onemocnění
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
CA2770493A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) * 2006-03-08 2010-03-23 Microsoft Corporation Multi-cache cooperation for response output caching
CN101495115A (zh) * 2006-08-02 2009-07-29 健赞股份有限公司 组合治疗
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
CA3116769C (en) 2018-10-30 2023-08-22 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
GB2218102B (en) 1988-04-08 1992-09-16 Sandoz Ltd Calcitonin peptide derivatives
ATE131471T1 (de) 1989-12-22 1995-12-15 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
EP0519748B1 (en) 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5352667A (en) 1991-11-22 1994-10-04 Ofer Lider Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them
AU3420693A (en) 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
JPH08505628A (ja) 1993-01-08 1996-06-18 田辺製薬株式会社 ペプチド型細胞接着阻害薬
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
CA2159192C (en) 1993-04-09 2006-07-25 Keiichi Tanaka Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
PL190866B1 (pl) * 1996-07-25 2006-02-28 Biogen Inhibitor adhezji komórek, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania

Also Published As

Publication number Publication date
EE04639B1 (et) 2006-06-15
EP1082302A1 (en) 2001-03-14
MXPA00011774A (es) 2002-10-17
AU4219299A (en) 1999-12-13
EE200000698A (et) 2002-06-17
BG65021B1 (bg) 2006-12-29
HUP0102255A2 (hu) 2001-11-28
DE69913687D1 (de) 2004-01-29
EA200001236A1 (ru) 2001-06-25
CZ20004425A3 (en) 2001-05-16
WO1999061421A1 (en) 1999-12-02
DE69913687T2 (de) 2004-10-07
EP1082302B1 (en) 2003-12-17
HUP0102255A3 (en) 2001-12-28
KR100636713B1 (ko) 2006-10-20
EA002988B1 (ru) 2002-12-26
ES2211096T3 (es) 2004-07-01
SK285280B6 (sk) 2006-10-05
JP2002516309A (ja) 2002-06-04
AU764108B2 (en) 2003-08-07
CZ298413B6 (cs) 2007-09-26
CA2333656A1 (en) 1999-12-02
NO20006023D0 (no) 2000-11-28
ZA200007300B (en) 2002-02-27
KR20010043906A (ko) 2001-05-25
NZ509199A (en) 2003-10-31
DK1082302T3 (da) 2004-04-26
PL344440A1 (en) 2001-11-05
IS5737A (is) 2000-11-28
CN1148350C (zh) 2004-05-05
BG105060A (en) 2001-08-31
IL139967A0 (en) 2002-02-10
SK18102000A3 (sk) 2001-07-10
US6495525B1 (en) 2002-12-17
NO317990B1 (no) 2005-01-17
UA65623C2 (en) 2004-04-15
PT1082302E (pt) 2004-04-30
YU75500A (sh) 2002-12-10
CN1307561A (zh) 2001-08-08
IL139967A (en) 2005-11-20
CA2333656C (en) 2008-07-29
NO20006023L (no) 2001-01-17
TR200100190T2 (tr) 2001-05-21
ATE256659T1 (de) 2004-01-15
SI1082302T1 (en) 2004-06-30
PL198189B1 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
HK1035726A1 (en) A vla-4 inhibitor: omepupa-v
GEP20063956B (en) Cell adhesion inhibitors
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
HUP0001285A3 (en) Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
HUP0300148A3 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0105144A3 (en) Hepatitis c inhibitor tri-peptides, process for production thereof, pharmaceutical compositions copmprising thereof, intermediates and their use
AU6523396A (en) Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing said inhibitors
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
GR3036305T3 (en) Chiral methyl phenyl oxazolidinones
MY125428A (en) ?-carboline drug products
WO2001090138A3 (en) SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
HUP0000288A3 (en) Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof
IL124883A0 (en) Amidino protease inhibitors and pharmaceutical compositions containing the same
BR9912010A (pt) Polimorfo de um produto farmacêutico
HUP0101899A3 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use
AU6611696A (en) N-(4-substituted-benzyl)-2-aminolactam derivatives
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
AU2003271811A1 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
AU6633596A (en) Improved therapeutic agents
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
HUP0204135A3 (en) Arnesyl transferase inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2001284477A1 (en) Novel crystals of N-hydroxy-2(S)-methyl-5-ethoxymethoxy -4(S)-(N-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090527